Boston Scientific vs DexCom, Inc.: Strategic Comparison

This in-depth comparison examines Boston Scientific and DexCom, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Boston Scientific on its own, evaluating DexCom, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Boston Scientific and DexCom, Inc. is widest.

On the headline numbers, annual revenue is $14.2B (FY2024) for Boston Scientific and $3.6B (FY2023) for DexCom, Inc., while their respective market capitalizations stand at $115.0B and $32.5B. DexCom, Inc. is headquartered in United States.

Boston Scientific: Boston Scientific Corporation (NYSE: BSX) is a global leader in medical solutions that improve the health of patients around the world, headquartered in Marlborough, Massachusetts. Founded in 1979 by medical technology pioneers John Abele and Pete Nicholas, Boston Scientific championed the revolution of less-invasive medicine—developing steerable catheters, vascular stents, and specialized implants that allow physicians to treat life-threatening conditions through small vascular punctures rather than traumatic open-cavity surgery. Today, Boston Scientific operates across three dedicated core segments: MedSurg (encompassing Endoscopy and Urology), Cardiovascular (comprising Interventional Cardiology, Peripheral Interventions, and the market-leading WATCHMAN franchise), and Neuromodulation (treating chronic pain and neurological movement disorders with spinal cord stimulation and deep brain stimulation). Serving more than 37 million patients annually across 130 countries, Boston Scientific invests over $1.4 billion annually in research and development to engineer breakthrough catheter and implant technologies that transform patient clinical outcomes. Under the transformative leadership of Chairman and CEO Michael F. Mahoney, Boston Scientific has delivered industry-leading organic revenue growth, expanded operating margins, and executed high-conviction strategic acquisitions (including BTG for $4.2B, Farapulse, and Axonics for $3.7B). Boston Scientific represents an institutional pillar within its global sector, maintaining expansive operations, robust customer and partner relationships, and mission-critical operating infrastructure. Operating on a significant scale across domestic and international markets, Boston Scientific continues to expand its technological and operational capabilities, integrating automated digital workflows, enterprise-grade data security protocols, and advanced operational systems to maximize service reliability and long-term operating efficiency. The enterprise remains focused on capital discipline, scalable operational economics, and strategic customer expansion across high-value market segments. continuous investment in specialized research, modern distribution networks, and skilled workforce development enables Boston Scientific to anticipate regulatory changes, mitigate emerging market risks, and deliver dependable performance for millions of clients, patients, or consumers worldwide.

DexCom, Inc.: From a tornado-hit Saint Paul music store in 1966 to a $43B retail powerhouse, Richard Schulze's Best Buy pioneered modern consumer tech superstores.

Boston Scientific and DexCom, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Boston Scientific and DexCom, Inc..

Boston Scientific business model: Boston Scientific operates a high-margin, resilient medical device business model built on single-use consumable catheters, implantable structural devices, and specialized capital equipment: (1) Cardiovascular (~62% of revenue / ~$8.8B), generating robust sales from coronary stents (Synergy), intravascular ultrasound (OptiCross), WATCHMAN left atrial appendage closure devices, and peripheral vascular atherectomy tools; (2) MedSurg (~29% of revenue / ~$4.1B), monetizing disposable endoscopes (Single-Use EXALT), stone management lithotripsy lasers, and urology implants; (3) Neuromodulation (~9% of revenue / ~$1.3B), delivering implantable neurostimulators (WaveWriter Alpha) and deep brain stimulation consoles; and (4) Capital-and-Consumable Placement: Consoles (such as FARASTAR pulsed field ablation generators and POLARx cryoablation consoles) are placed in hospital catheterization labs, locking electrophysiologists into continuous, recurring daily utilization of high-margin single-use catheters. Boston Scientific maintains gross margins above 70% and generates over $2.1 billion in annual free cash flow.

DexCom, Inc. business model: Best Buy operates an omnichannel specialty retail and services model. It generates revenue through high-volume product sales (computers, televisions, appliances, smartphones), vendor-funded showroom partnerships (store-within-a-store displays with Apple, Samsung, and Microsoft), paid Geek Squad repairs, and recurring My Best Buy Total subscriptions.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Boston Scientific stack up against those of DexCom, Inc..

Specific competitive-advantage data for Boston Scientific is limited, though Boston Scientific defends its position against DexCom, Inc. through scale and brand.

DexCom, Inc. competitive advantage: Best Buy's enduring moat combines an extensive physical store footprint enabling 1-hour in-store pickup, dedicated vendor-funded boutique displays, expert non-commissioned sales consultations, and the trusted nationwide in-home Geek Squad service fleet.

Future prospects matter as much as current results. The growth strategies below explain how Boston Scientific and DexCom, Inc. each plan to expand from here.

Boston Scientific growth strategy: Under CEO Michael Mahoney, Boston Scientific is executing a clear four-pronged growth strategy: (1) Scaling Global FARAPULSE Adoption: Expanding manufacturing capacity and commercial distribution across North America, Europe, and Asia-Pacific to convert conventional thermal cardiac ablations to pulsed field ablation; (2) Expanding WATCHMAN Indications: Advancing the CHAMPION-AF clinical trial to expand WATCHMAN label indications as a first-line alternative to direct oral anticoagulants (DOACs); (3) Accelerating Endoscopy Single-Use Transition: Commercializing single-use duodenoscopes and bronchoscopes (EXALT platform) to eliminate the risk of hospital patient cross-contamination associated with reprocessed reusable endoscopes; and (4) Expanding Neuromodulation & Pelvic Health via Axonics: Integrating the $3.7B acquisition of Axonics to capture the multi-billion-dollar sacral neuromodulation market for urinary and bowel dysfunction.

DexCom, Inc. growth strategy: Expanding high-margin paid membership tiers (My Best Buy Total), accelerating digital retail media network advertising, growing healthcare monitoring tech, and optimizing store formats for faster omnichannel fulfillment.

A closer look at the financial trajectory of Boston Scientific and DexCom, Inc. rounds out the comparison.

Boston Scientific: Boston Scientific exhibits an exceptional financial profile characterized by high organic top-line compounding, expanding operating leverage, and robust capital generation. In fiscal year 2024, Boston Scientific generated consolidated net sales of $14.24 billion, representing 15.5% reported growth and over 13% organic growth. GAAP net income reached $1.571 billion, with adjusted operating margin expanding to 26.8%. The company generated over $2.4 billion in operating cash flow, maintaining an investment-grade balance sheet with a net debt-to-EBITDA ratio below 2.2x and deploying capital toward strategic growth acquisitions and opportunistic share repurchases.

DexCom, Inc.: In FY2024, Best Buy generated $43.45 billion in total revenue and $1.24 billion in GAAP net income, generating over $2.1 billion in operating cash flow while returning over $1.1 billion to shareholders via dividends and share repurchases.